TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28633773
Drug: Therapeutic ultrasound
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic ultrasound (US) therapy - 15 sessions (1 mHz; 2 W/cm2)
Study: 21813443
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL of PRP
Study: 21813443
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL of autologous blood
Study: 17538085
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (decompressive laminectomy with or without fusion)
Study: 17538085
Drug: Nonsurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical treatment (usual nonsurgical care)
Study: 11431663
Drug: Dofetilide 500
Normalized name: DOFETILIDE 500MCG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dofetilide 500 microg twice daily
Study: 11431663
Drug: Propafenone 150
Normalized name: propafenone 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 150 mg three times a day
Study: 9529685
Drug: Oral terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbinafine 250 mg daily for 12 weeks
Study: 2018012
Drug: Metoprolol CR,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol CR, 200 mg once daily
Study: 2018012
Drug: Nifedipine retard
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine retard 20 mg twice daily
Study: 31089856
Drug: Productive failure
Normalized name: INVESTIGATIONAL CONGESTIVE HEART FAILURE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Productive failure (attempt to generate solutions before receiving instruction)
Study: 19284108
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of magnetopuncture and phytoaeroionotherapeutic chronocorrection
Study: 19284108
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of soft‐tissue manual therapy
Study: 17547587
Drug: Quetiapine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (600 and 300 mg/day)
Study: 14999693
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics (ofloxacin 200 mg i.v. q12h for 2 days followed by oral ofloxacin 200 mg q12h for 5 days)
Study: 14999693
Drug: On-demand antibiotics
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand antibiotics
Study: 8461240
Drug: Sustained-release ibuprofen
Normalized name: ibuprofen Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release ibuprofen (once-daily dosing)
Study: 8461240
Drug: Conventional-release ibuprofen
Normalized name: ibuprofen Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-release ibuprofen (400 mg four times daily)
Study: 28335697
Drug: Individually tailored
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually tailored cognitive-behavioral therapy program
Study: 22962239
Drug: Deworming tablet
Normalized name: oxfendazole
DrugBank: Oxfendazole (DB11446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deworming tablet (400 mg albendazole) once in six months
Study: 22962239
Drug: Deworming tablet
Normalized name: oxfendazole
DrugBank: Oxfendazole (DB11446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deworming tablet (400 mg albendazole) plus weekly Iron-Folic acid (60 mg elemental iron and 0.5 mg folic acid)
Study: 1812477
Drug: Theophylline retard
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline retard preparation administered once daily in addition to baseline medication
Study: 30417636
Drug: SQ HDM
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ HDM SLIT-tablet (ACARIZAX®) as add-on to pharmacotherapy
Study: 27339453
Drug: Resveratrol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (500 mg capsules, twice daily for 4 weeks)
Study: 27339453
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mg neutral microcellulose capsules, twice daily for 4 weeks)
Study: 23066166
Drug: Combined B-vitamin
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined B-vitamin treatment (folic acid 2.5mg, vitamin B(6) 50mg, vitamin B(12) 1mg)
Study: 23066166
Drug: Combined B-vitamin
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined B-vitamin treatment
Study: 16276166
Drug: Low-dose hydrocortisone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hydrocortisone (50-mg bolus followed by a continuous infusion of 0.18 mg/kg body weight/hr, reduced to 0.06 mg/kg/hr after shock reversal)
Study: 11924224
Drug: Chewing sugar-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewing sugar-free gum (sorbitol-sweetened), 1 stick for 15-20 minutes after meals, three times daily
Study: 9701189
Drug: Tomato-based juice
Normalized name: tomato juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato-based juice supplemented with vitamin C (600 mg), vitamin E (400 IU), and beta-carotene (30 mg)
Study: 2528221
Drug: Metronidazole 1%
Normalized name: METRONIDAZOLE 1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 1% cream applied twice daily
Study: 17374331
Drug: Methotrexate therapy
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate therapy
Study: 1182676
Drug: Methotrexate in
Normalized name: methotrexate Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate in combination with other drugs
Study: 26119672
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with negative emmprin expression
Study: 15644672
Drug: Early Parenteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early Parenteral Nutrition (PN)
Study: 8748367
Drug: i.v. nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. nutrition plus triple therapy (heparin, hydrocortisone, glyceryl trinitrate patch)
Study: 6795122
Drug: O-acetyl-negative polysaccharide
Normalized name: O-acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: O-acetyl-negative polysaccharide vaccine
Study: 6795122
Drug: O-acetyl-positive polysaccharide
Normalized name: O-acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: O-acetyl-positive polysaccharide vaccine
Study: 29890569
Drug: Sitagliptin 50
Normalized name: SITagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 50 mg daily plus placebo
Study: 29890569
Drug: Sitagliptin 50
Normalized name: SITagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 50 mg daily plus synbiotic
Study: 8757085
Drug: Poplar bud
Normalized name: Clove buds
DrugBank: Clove (DB10672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poplar bud ointment saturated with trace metal elements
Study: 1722835
Drug: Ointments with
Normalized name: urea Topical Ointment [Aquaphilic with Urea]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointments with antibiotics and antiseptics on a fat base (Control)
Study: 17157339
Drug: 10-steroid profile
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-steroid profile measured by tandem mass spectrometry during high dose cortrosyn stimulation test
Study: 17157339
Drug: Three-steroid profile
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-steroid profile
Study: 17157339
Drug: 11-deoxycortisol, dehydroepiandrosterone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11-deoxycortisol, dehydroepiandrosterone, and two-steroid profile
Study: 17157339
Drug: Stimulated levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulated levels of aldosterone, 11-deoxycortisol, dehydroepiandrosterone, and two- or three-steroid profile
Study: 17157339
Drug: Steroid profile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid profile measuring cortisol, aldosterone, 11-deoxycortisol, and dehydroepiandrosterone
Study: 15750416
Drug: Low-dose inductive
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose inductive chemotherapy, surgery, and then radiotherapy
Study: 15750416
Drug: Neoadjuvant cytostatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant cytostatic treatment with adequate tissue regression
Study: 15750416
Drug: Changes in
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changes in expressions of laminin and syndecan-1 in response to cytostatic treatment
Study: 10617008
Drug: Intraoperative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative administration of 3000 IU of antithrombin III (AT III) concentrates plus heparin (Group A)
Study: 10617008
Drug: Heparin only
Normalized name: Heparin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin only (Group B)
Study: 6250928
Drug: Antacid gel
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antacid gel (magnesium and aluminium hydroxide)
Study: 27820728
Drug: 100-times stretching
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-times stretching treatment
Study: 27820728
Drug: 50-times stretching
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50-times stretching treatment
Study: 22403970
Drug: Prophylactic inhalation
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic inhalation of isopropyl alcohol (IPA) vapors with IV ondansetron
Study: 17524288
Drug: OraSure oral
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OraSure oral fluid testing
Study: 7987882
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day simvastatin
Study: 7987882
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day simvastatin
Study: 2547465
Drug: Intravenous doses
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous doses of lisinopril
Study: 2547465
Drug: Oral doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doses of lisinopril (10 daily doses, q24h)
Study: 5302328
Drug: Whole-cell cholera
Normalized name: cholera, inactivated, whole cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-cell cholera vaccine, 0.5 ml dose
Study: 5302328
Drug: Purified Ogawa
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified Ogawa antigen, 100 mug dose
Study: 5302328
Drug: Whole-cell cholera
Normalized name: cholera, inactivated, whole cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-cell cholera vaccine, 0.4 ml dose
Study: 5302328
Drug: Whole-cell cholera
Normalized name: cholera, inactivated, whole cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-cell cholera vaccine
Study: 29151315
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day oral iron for 3 months
Study: 29151315
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo for 3 months
Study: 23680766
Drug: agalsidase alfa
Normalized name: Agalsidase alfa
DrugBank: Agalsidase alfa (DB15874)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: agalsidase alfa (0.2 mg/kg every other week for 12 months)
Study: 22012809
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of tranexamic acid (loading dose of 500 mg before surgery followed by continuous infusion of 250 mg/h during surgery)
Study: 22012809
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of tranexamic acid
Study: 22012809
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of tranexamic acid and placebo
Study: 19691851
Drug: Artesunate and
Normalized name: artesunate and mefloquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate and amodiaquine fixed dose combination (FDC)
Study: 19691851
Drug: Artesunate and
Normalized name: artesunate and mefloquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate and amodiaquine given in separate tablets
Study: 9118699
Drug: L‐5‐hydroxytryptophan (L‐5‐HTP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐5‐hydroxytryptophan (L‐5‐HTP), 0.4 mg/kg
Study: 28581398
Drug: Dose-escalated external
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-escalated external beam (DE‐EBRT) boost
Study: 28581398
Drug: Low-dose-rate prostate
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose-rate prostate brachytherapy (LDR‐PB) boost
Study: 26621252
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication at baseline
Study: 26621252
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication at follow up
Study: 14500473
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of MCC-TT vaccine
Study: 14500473
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of MCC-TT vaccine
Study: 14500473
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of MCC-TT vaccine
Study: 1394812
Drug: Intravesical thio-TEPA
Normalized name: thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravesical thio-TEPA at 30 mg/30 ml physiological saline, instilled 32 times over 2 years (group T)
Study: 1394812
Drug: Oral UFT
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral UFT given at 1296 mg/day for 2 years (group U)
Study: 1394812
Drug: No prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prophylactic treatment (group C)
Study: 1394812
Drug: Oral UFT
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral UFT (group U)
Study: 3900847
Drug: Tocopherol treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocopherol treatment (early parenteral tocopherol given from day one)
Study: 19840063
Drug: Xanthigen-600/2.4 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xanthigen-600/2.4 mg (300 mg PSO + 300 mg brown seaweed extract containing 2.4 mg fucoxanthin)
Study: 19840063
Drug: Fucoxanthin (>
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fucoxanthin (> 2.4 mg)
Study: 19840063
Drug: Xanthigen-400/1.6 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xanthigen-400/1.6 mg (200 mg PSO + 200 mg brown seaweed extract containing 1.6 mg fucoxanthin)
Study: 16982237
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no suppository treatment)
Study: 1999775
Drug: Children with
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children with prevaccination antibody > 0.15 microgram/ml
Study: 1999775
Drug: Children with
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children with prevaccination antibody ≤ 0.15 microgram/ml
Study: 6141317
Drug: Beta-blocker group
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker group (Atenolol)
Study: 6141317
Drug: Diuretic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic group (Hydrochlorothiazide)
Study: 29431146
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment plus hyperbaric oxygen therapy (HBOT)
Study: 26353751
Drug: Fixed Tc‐99m
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed Tc‐99m tetrofosmin tracer dose
Study: 22864525
Drug: Intratympanic gadolinium
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratympanic gadolinium injection (gadolinium‐diethylene‐triamine pentaacetic acid diluted eightfold with saline)
Study: 22864525
Drug: Intravenous gadolinium
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous gadolinium injection (double dose of gadoteridol (0.5 mmol/ml); 0.2 mmol/kg body weight)
Study: 22864525
Drug: Intratympanic gadolinium
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratympanic gadolinium injection
Study: 22864525
Drug: Intravenous gadolinium
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous gadolinium injection
Study: 17475531
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous insulin infusion (CSII) with bolus optimization and sulfonylurea at bedtime
Study: 17475531
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous insulin infusion (CSII) with basal rate optimization and sulfonylurea before meals
Study: 16091670
Drug: Lifestyle intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifestyle intervention (addition to pharmacological therapy)
Study: 12041718
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol 3350 (10 g/m2/day)
Study: 12041718
Drug: Lactulose (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (1.3 g/kg/d divided twice daily up to 20 g)
Study: 21383291
Drug: 3-day oral
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-day oral aprepitant regimen (125 mg on day 1, 80 mg on day 2, 80 mg on day 3)
Study: 21383291
Drug: Single-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose intravenous fosaprepitant (150 mg on day 1)
Study: 10583029
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (0.44 mg day-1, 0.88 mg day-1, 1.76 mg day-1)
Study: 10583029
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (5 mg day-1, 10 mg day-1, 20 mg day-1)
Study: 1652264
Drug: 0.07 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.07 mg/kg pipecuronium
Study: 1652264
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg pipecuronium
Study: 6848299
Drug: Atenolol 400
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol 400 mg
Study: 18704471
Drug: Fexofenadine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine (60 mg BD)
Study: 18704471
Drug: Cumulative amount
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative amount of airborne pollen during the treatment period
Study: 11982836
Drug: Oxycodone premedication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone premedication with halothane
Study: 11982836
Drug: Halothane without
Normalized name: Halothane
DrugBank: Halothane (DB01159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Halothane without oxycodone
Study: 11982836
Drug: Sevoflurane without
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane without oxycodone
Study: 11982836
Drug: Oxycodone premedication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone premedication with sevoflurane
Study: 10593449
Drug: Olanzapine 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 12.5 mg/day for the first week, then 25 mg/day for the remaining weeks (8 weeks total)
Study: 8618109
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil 10 mg/kg bid for 5 days
Study: 8618109
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil 10 mg/kg bid for 10 days
Study: 2169839
Drug: Lactulose (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (15 ml bd)
Study: 2169839
Drug: High-fibre diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fibre diet (30-40 g daily)
Study: 7398187
Drug: Magnesium-aluminum hydroxide
Normalized name: Magnesium Aluminum Silicate
DrugBank: Magnesium Aluminum Silicate (DB11230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium-aluminum hydroxide gel 30 ml
Study: 31672946
Drug: Customized Health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Customized Health Promotion Program (CHPP) for 10 weeks, weekly sessions, including coping strategies, lifestyle modification, emotional support, and exercise three times a week at home
Study: 17852171
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment (n = 177)
Study: 15745977
Drug: Intrapleural streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural streptokinase (250,000 IU twice daily for three days)
Study: 12414852
Drug: Levothyroxine (L-T(4))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine (L-T(4))
Study: 1742507
Drug: Oral bismuth
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bismuth therapy
Study: 6125728
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg acyclovir by mouth five times a day for 5 days
Study: 29659406
Drug: Topical BTX‐A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical BTX‐A liposomal cream
Study: 26704774
Drug: Morphine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.1 mg/kg) plus lidocaine (1.5 mg/kg)
Study: 26704774
Drug: Morphine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.1 mg/kg) plus normal saline 0.9% (placebo)